Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Fecal microbiota transplantation and its repercussions in patients with melanoma refractory to anti-PD-1 therapy: scope review.Revista do Colegio Brasileiro de Cirurgioes · 2023
   Article
2. Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy.Cancers · 2022
   Review
3. Iron oxide nanoparticles for immune cell labeling and cancer immunotherapy.Nanoscale horizons · 2021
   Review
4. The Role of the Cervicovaginal Microbiome on the Genesis and as a Biomarker of Premalignant Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer.International journal of molecular sciences · 2019
   Review
5. The Clinical Link between Human Intestinal Microbiota and Systemic Cancer Therapy.International journal of molecular sciences · 2019
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as